BG106321A - Нови производни на карбоксилната киселина с 5,6-заместено пиримидиново ядро, тяхното получаване и използването им като антагонисти на ендотелиновия рецептор - Google Patents

Нови производни на карбоксилната киселина с 5,6-заместено пиримидиново ядро, тяхното получаване и използването им като антагонисти на ендотелиновия рецептор

Info

Publication number
BG106321A
BG106321A BG106321A BG10632102A BG106321A BG 106321 A BG106321 A BG 106321A BG 106321 A BG106321 A BG 106321A BG 10632102 A BG10632102 A BG 10632102A BG 106321 A BG106321 A BG 106321A
Authority
BG
Bulgaria
Prior art keywords
utilization
production
carboxylic acid
acid derivatives
receptor antagonists
Prior art date
Application number
BG106321A
Other languages
English (en)
Inventor
Wilhelm Amberg
Georg Kettschau
Original Assignee
Abbott Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co. Kg filed Critical Abbott Gmbh & Co. Kg
Publication of BG106321A publication Critical patent/BG106321A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретението се отнася до съединения с формула@@в която заместителите имат значенията, посочени в описанието, както и до тяхното използване.
BG106321A 1999-07-20 2002-01-18 Нови производни на карбоксилната киселина с 5,6-заместено пиримидиново ядро, тяхното получаване и използването им като антагонисти на ендотелиновия рецептор BG106321A (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19933164A DE19933164A1 (de) 1999-07-20 1999-07-20 Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten
PCT/EP2000/006293 WO2001005771A1 (de) 1999-07-20 2000-07-05 Neue carbonsäurederivate mit 5,6 substituiertem pyrimidinring, ihre herstellung und verwendung als endothelin rezeptorantagonisten

Publications (1)

Publication Number Publication Date
BG106321A true BG106321A (bg) 2002-08-30

Family

ID=7914884

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106321A BG106321A (bg) 1999-07-20 2002-01-18 Нови производни на карбоксилната киселина с 5,6-заместено пиримидиново ядро, тяхното получаване и използването им като антагонисти на ендотелиновия рецептор

Country Status (21)

Country Link
EP (1) EP1196394A1 (bg)
JP (1) JP2003505377A (bg)
KR (1) KR20020019550A (bg)
CN (1) CN1367778A (bg)
AR (1) AR030026A1 (bg)
AU (1) AU6561500A (bg)
BG (1) BG106321A (bg)
BR (1) BR0012592A (bg)
CA (1) CA2379545A1 (bg)
CZ (1) CZ2002190A3 (bg)
DE (1) DE19933164A1 (bg)
HU (1) HUP0202646A3 (bg)
IL (1) IL147666A0 (bg)
MX (1) MXPA02000616A (bg)
NO (1) NO20020254L (bg)
PL (1) PL353165A1 (bg)
SK (1) SK772002A3 (bg)
TR (1) TR200200622T2 (bg)
TW (1) TW555749B (bg)
WO (1) WO2001005771A1 (bg)
ZA (1) ZA200200333B (bg)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2462065T3 (es) * 2009-07-10 2014-05-22 Cadila Healthcare Limited Proceso mejorado para la preparación de Ambrisentán e intermedios novedosos de este
WO2011114338A1 (en) 2010-03-15 2011-09-22 Natco Pharma Limited A process for the preparation of highly pure ambrisentan

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19636046A1 (de) * 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
ID24278A (id) * 1997-10-31 2000-07-13 Basf Ag Turunan-turunan asam karboksilat baru dengan rantai sisi amida, pembuatan dan penggunaannya sebagai reseptor antagonis endotelin

Also Published As

Publication number Publication date
ZA200200333B (en) 2003-04-30
AU6561500A (en) 2001-02-05
TW555749B (en) 2003-10-01
KR20020019550A (ko) 2002-03-12
CA2379545A1 (en) 2001-01-25
NO20020254D0 (no) 2002-01-17
AR030026A1 (es) 2003-08-13
WO2001005771A1 (de) 2001-01-25
PL353165A1 (en) 2003-10-20
HUP0202646A3 (en) 2003-03-28
TR200200622T2 (bg) 2002-06-21
CN1367778A (zh) 2002-09-04
JP2003505377A (ja) 2003-02-12
DE19933164A1 (de) 2001-01-25
EP1196394A1 (de) 2002-04-17
IL147666A0 (en) 2002-08-14
BR0012592A (pt) 2002-05-28
MXPA02000616A (es) 2002-08-30
CZ2002190A3 (cs) 2003-08-13
SK772002A3 (en) 2003-01-09
HUP0202646A2 (hu) 2003-02-28
NO20020254L (no) 2002-02-20

Similar Documents

Publication Publication Date Title
CA2379026A1 (en) Substituted thiene-3-yl-sulphonylamino(thio)carbonyl-triazolin(thi)ones
CA2319275A1 (en) Bicyclic pyridine and pyrimidine derivatives as neuropeptide y receptor antagonists
IL155875A0 (en) Piperazinylpyrazines compounds as antagonists of serotonin 5-ht2 receptor
TR200000333T2 (tr) Y alıcı antagonistleri olarak 4-aminopirol (3,2-d) pirimidinler.
SE9702773D0 (sv) Novel compounds
BG104831A (bg) Заместени с хетероцикли амиди, получаването им и използването им
TR199900486T2 (xx) Aziniloksi ve fenoksi-diaril-karbonasit t�revleri.
NO995114L (no) Festeanordning for å forbinde to deler med hverandre, samt anvendelse av festeanordningen
AU1783201A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG105689A (bg) Използване на пирамидинови производни за профилактика и терапия на церебрална исхемия
BG105847A (bg) Калцилитни съединения
MXPA04006571A (es) Derivado de pirimidina biciclica fusionada.
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
TR200001182T2 (tr) Yeni karbonik asit türevleri, üretimleri ve kullanımları.
SE9903290D0 (sv) Novel compounds
AU1781601A (en) 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
BG104022A (bg) Нови производни на бета-амино- и бета-азидокарбоксилна киселина, тяхното получаване и използването им като антагонисти на ендотелинов рецептор
BG106321A (bg) Нови производни на карбоксилната киселина с 5,6-заместено пиримидиново ядро, тяхното получаване и използването им като антагонисти на ендотелиновия рецептор
BG103502A (bg) Хетероциклени производни на карбоксилни киселини,тяхното получаване и използването им като антагонисти на ендотели- нови рецептори
MXPA02001406A (es) Heterociclilos-2h-cromenos substituidos.
TR200001080T2 (tr) 2 ile ikame edilmiş 1,2-Benisotiyazol türevleri ve bunların serrotonın antagonistleri
AU2001293791A1 (en) Process for the preparation of vitronectin receptor antagonists
IL134276A0 (en) Novel carboxylic acid derivatives, their production and their use as mixed eta/etb endothelin-receptor antagonists
BG106154A (bg) Производни на карбоксилна киселина с арил заместени, съдържащи азот хетероцикли, метод за получаването им и използването им като антагонисти на ендотелинови рецептори
AU3027199A (en) 5-substituted pyrimidine-2-yloxy carboxylic acid derivatives, the production of the same and their utilization as endothelin antagonists